Wall Street analysts predict that Paratek Pharmaceuticals Inc (NASDAQ:PRTK) will post $6.91 million in sales for the current quarter, according to Zacks Investment Research. Six analysts have provided estimates for Paratek Pharmaceuticals’ earnings. The lowest sales estimate is $150,000.00 and the highest is $12.00 million. Paratek Pharmaceuticals posted sales of $10,000.00 during the same quarter last year, which suggests a positive year over year growth rate of 69,000%. The company is scheduled to report its next quarterly earnings report after the market closes on Tuesday, November 6th.
According to Zacks, analysts expect that Paratek Pharmaceuticals will report full-year sales of $18.09 million for the current financial year, with estimates ranging from $50,000.00 to $69.84 million. For the next financial year, analysts forecast that the business will report sales of $32.40 million, with estimates ranging from $12.90 million to $95.30 million. Zacks’ sales calculations are a mean average based on a survey of sell-side research firms that cover Paratek Pharmaceuticals.
Paratek Pharmaceuticals (NASDAQ:PRTK) last posted its quarterly earnings data on Thursday, August 2nd. The specialty pharmaceutical company reported ($0.94) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.92) by ($0.02). Paratek Pharmaceuticals had a negative net margin of 1,961.41% and a negative return on equity of 106.39%. The company had revenue of $0.04 million for the quarter, compared to analyst estimates of $0.10 million.
Several equities analysts have recently issued reports on PRTK shares. Zacks Investment Research downgraded shares of Paratek Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday, July 11th. Cantor Fitzgerald reiterated a “buy” rating and issued a $50.00 target price on shares of Paratek Pharmaceuticals in a research report on Thursday, August 2nd. Wedbush set a $20.00 target price on Paratek Pharmaceuticals and gave the company a “buy” rating in a research report on Thursday, August 9th. Bank of America assumed coverage on Paratek Pharmaceuticals in a research report on Monday, August 27th. They issued a “neutral” rating and a $13.00 target price on the stock. Finally, ValuEngine upgraded Paratek Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Tuesday, October 2nd. Two research analysts have rated the stock with a sell rating, two have issued a hold rating and seven have given a buy rating to the company. Paratek Pharmaceuticals presently has a consensus rating of “Hold” and a consensus price target of $30.29.
In other Paratek Pharmaceuticals news, COO Evan Loh sold 8,861 shares of the company’s stock in a transaction that occurred on Wednesday, October 3rd. The stock was sold at an average price of $9.82, for a total value of $87,015.02. Following the sale, the chief operating officer now owns 235,286 shares in the company, valued at approximately $2,310,508.52. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, VP Adam Woodrow sold 8,750 shares of the company’s stock in a transaction that occurred on Wednesday, October 3rd. The stock was sold at an average price of $9.82, for a total value of $85,925.00. Following the completion of the sale, the vice president now owns 112,917 shares in the company, valued at approximately $1,108,844.94. The disclosure for this sale can be found here. In the last quarter, insiders sold 58,446 shares of company stock worth $559,369. 6.20% of the stock is owned by insiders.
A number of institutional investors have recently added to or reduced their stakes in the business. General American Investors Co. Inc. boosted its position in Paratek Pharmaceuticals by 12.9% in the 3rd quarter. General American Investors Co. Inc. now owns 436,364 shares of the specialty pharmaceutical company’s stock worth $4,233,000 after purchasing an additional 50,000 shares in the last quarter. Alps Advisors Inc. boosted its position in Paratek Pharmaceuticals by 22.5% in the 3rd quarter. Alps Advisors Inc. now owns 56,149 shares of the specialty pharmaceutical company’s stock worth $545,000 after purchasing an additional 10,296 shares in the last quarter. Northern Trust Corp boosted its position in Paratek Pharmaceuticals by 13.1% in the 2nd quarter. Northern Trust Corp now owns 408,846 shares of the specialty pharmaceutical company’s stock worth $4,170,000 after purchasing an additional 47,440 shares in the last quarter. Bank of New York Mellon Corp boosted its position in Paratek Pharmaceuticals by 10.2% in the 2nd quarter. Bank of New York Mellon Corp now owns 129,044 shares of the specialty pharmaceutical company’s stock worth $1,316,000 after purchasing an additional 11,980 shares in the last quarter. Finally, Granahan Investment Management Inc. MA purchased a new stake in Paratek Pharmaceuticals in the 2nd quarter worth approximately $1,801,000. Institutional investors and hedge funds own 77.29% of the company’s stock.
PRTK opened at $7.45 on Thursday. Paratek Pharmaceuticals has a 52-week low of $7.22 and a 52-week high of $22.80. The company has a debt-to-equity ratio of 2.37, a quick ratio of 7.88 and a current ratio of 7.88. The stock has a market cap of $248.76 million, a PE ratio of -2.26 and a beta of 0.57.
Paratek Pharmaceuticals Company Profile
Paratek Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics based upon tetracycline chemistry in the United States. Its lead product candidates include omadacycline, an intravenous and oral antibiotic for use as a monotherapy antibiotic for acute bacterial skin and skin structure infections, community-acquired bacterial pneumonia, urinary tract infections, and other community-acquired bacterial infections; and Sarecycline, a tetracycline-derived compound designed for use in the treatment of acne and rosacea.
See Also: Earnings Per Share
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Paratek Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Paratek Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.